Spectrum Pharmaceuticals Announces Dr. Francois Lebel as Chief Medical Officer
October 18 2018 - 7:00AM
Business Wire
Veteran of the Biopharmaceutical Industry Joins
as Company Advances Two Late-stage Oncology Therapies
Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology
company with fully integrated commercial and drug development
operations with a primary focus in hematology and oncology, today
announced the appointment of Francois Lebel, M.D., F.R.C.P.C. as
Chief Medical Officer, effective November 5, 2018.
“Dr. Lebel is an accomplished leader and has deep expertise in
biopharmaceuticals with an emphasis in oncology drug development,”
said Joe Turgeon, President and CEO of Spectrum Pharmaceuticals.
“Given his qualifications, we believe Dr. Lebel will add
significant value to Spectrum and our clinical programs. We have
several near-term milestones and priorities including expanding the
development of poziotinib in broader patient populations, gaining
regulatory clarity for breakthrough designation on poziotinib, and
filing the ROLONTIS BLA in the fourth quarter.”
Dr. Lebel will be responsible for leading the Spectrum clinical
program which includes directing the clinical research staff,
overseeing the company’s ongoing clinical trials, and regulatory
submissions. He will also direct clinical development strategies,
life-cycle management, relationships with regulatory bodies and
provide strategic counsel on all business development
activities.
“It is a great time to have the opportunity to lead the medical
and scientific organization at Spectrum ahead of multiple FDA
submissions,” said Francois Lebel, M.D., F.R.C.P.C, Chief Medical
Officer of Spectrum Pharmaceuticals. “In evaluating Spectrum's
pipeline drugs, I have been very impressed with the robust clinical
data, especially the recently released poziotinib data in heavily
pretreated lung cancer patients who have very few
options. I plan to aggressively expand the utility of this
targeted therapy in areas of high unmet medical need. I look
forward to leading Spectrum into a new era in medical and clinical
development with the goal of significantly advancing patient
care in oncology.”
Dr. Lebel brings nearly 30 years of clinical leadership
experience within the biopharmaceutical industry. He has designed
and managed global medical organizations to deliver results,
enhance productivity and practice sound risk management. Most
recently, he served as the Executive Vice President of Research
& Development, Chief Medical Officer at ZIOPHARM Oncology. He
also held various leadership roles including Vice President of
Research & Development at Baxter International and Global Head
of Medical and Scientific Affairs at MedImmune. In the last 25
years, he provided strategic leadership on eight NDA/BLAs in
various therapeutic areas and on a number of mergers and
acquisitions. Dr. Lebel has broad and deep experience in
oncology drug development, medical affairs, regulatory and
pharmacovigilance acquired through various roles of increasing
responsibilities at Chiron (Novartis), Warner-Lambert (Pfizer) and
Burroughs Wellcome (GSK). He received his medical degree from the
University of Ottawa, Canada, and he completed his post
graduate training at McGill University and Harvard Medical School.
He is Board Certified in Internal Medicine and a fellow of the
Royal College of Physicians of Canada.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biopharmaceutical
company focused on acquiring, developing, and commercializing drug
products, with a primary focus in hematology and oncology. Spectrum
currently markets six hematology/oncology drugs, and has an
advanced stage pipeline that has the potential to transform
the company. Spectrum's strong track record for in-licensing and
acquiring differentiated drugs, and expertise in clinical
development have generated a robust, diversified, and growing
pipeline of product candidates in advanced-stage Phase 2 and Phase
3 studies. More information on Spectrum is available
at www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of Spectrum Pharmaceuticals that involve risks and
uncertainties that could cause actual results to differ materially.
These statements are based on management's current beliefs and
expectations. These statements include, but are not limited to,
statements that relate to Spectrum’s business and its future,
including certain company milestones, Spectrum's ability to
identify, acquire, develop and commercialize a broad and diverse
pipeline of late-stage clinical and commercial products, the timing
and results of FDA decisions, and any statements that relate to the
intent, belief, plans or expectations of Spectrum or its
management, or that are not a statement of historical fact. Risks
that could cause actual results to differ include the possibility
that Spectrum’s existing and new drug candidates may not prove safe
or effective, the possibility that our existing and new
applications to the FDA and other regulatory agencies may not
receive approval in a timely manner or at all, the possibility that
our existing and new drug candidates, if approved, may not be more
effective, safer or more cost efficient than competing drugs, the
possibility that our efforts to acquire or in-license and develop
additional drug candidates may fail, our dependence on third
parties for clinical trials, manufacturing, distribution and
quality control and other risks that are described in further
detail in the company's reports filed with the Securities and
Exchange Commission. The company does not plan to update any such
forward-looking statements and expressly disclaims any duty to
update the information contained in this press release except as
required by law.
SPECTRUM PHARMACEUTICALS, INC.® is a registered trademark of
Spectrum Pharmaceuticals, Inc. and its affiliate. REDEFINING CANCER
CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned
by Spectrum Pharmaceuticals, Inc. Any other trademarks are the
property of their respective owners.
© 2018 Spectrum Pharmaceuticals, Inc. All Rights Reserved
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181018005238/en/
Spectrum Pharmaceuticals, Inc.Shiv KapoorVice President,
Strategic Planning & Investor
Relations702-835-6300InvestorRelations@sppirx.com
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Spectrum Pharmaceuticals (NASDAQ:SPPI)
Historical Stock Chart
From Apr 2023 to Apr 2024